Abstract: The present invention relates to the field of Immunology, specifically with the branch of Immuno-Allergy and in particular with the use of adjuvant or carrier compounds, capable of modulating the immune response to allergens. The technical objective that is pursued is to obtain a pharmaceutical preparation of therapeutic or prophylactic use using bacterial proteoliposomes, which transform the allergic response Th2 and IgE when being applied in allergic individuals, toward a protector response Th1; as well as it is able to prevent the appearance and the development of allergies in individuals non-allergic yet. The vaccine composition consists of proteoliposomes derived from Gram-negative bacteria coupled to allergens and optionally contains other adjuvants or antigens. The method for its preparation and an immunization scheme of two doses are provided.

Abstract: Methods and compositions for treating disease using human subgroup B adenovirus, vectors derived from such viruses, including expression vector systems in which one or more subgroup B adenoviral genes are replaced by a foreign gene.

Abstract: The invention provides compositions a methods of identifying and testing therapeutics against HSV infection, and in particular, compositions comprising receptors which enable cell specific entry of HSV. The invention also provides a novel DNA sequence that encodes a protein B5T74 that confers the ability of herpes simplex virus (HSV) to infect and replicate in otherwise non-permissive cells. Also provided are vectors comprising the isolated nucleic acids encoding HSV receptors in host suitable for expression of the nucleic acids encoding the HSV receptors, fragments of the HSV receptors, or homologs of the HSV receptor. Further provided is a porcine cell system which expresses a herpes simplex virus receptor, but does not express endogenous, HSV entry receptors.